News Release 

IASLC announces 2020 World Conference on Lung Cancer Virtual Presidential Symposium presentations

International Association for the Study of Lung Cancer

International Association for the Study of Lung Cancer Announces Research Presentations for the 2020 World Conference on Lung Cancer Virtual Presidential Symposium Saturday, August 8

What: The International Association for the Study of Lung Cancer (IASLC) hosts a Virtual Presidential Symposium for the 2020 World Conference on Lung Cancer

When: Saturday, August 8, 2020--4 a.m. in Los Angeles; 7 a.m. in New York; 1 p.m. in Vienna; 7 p.m. in Singapore.

Presidential Symposium: Each IASLC World Conference on Lung Cancer (WCLC) highlights the best lung cancer research at its Presidential Symposium. Due to the COVID-19 pandemic, the 2020 WCLC was postponed and restructured as a two-part event. Part 1, the Virtual Presidential Symposium is a complimentary symposium and a prelude to the new innovative research that will be presented at the all-virtual WCLC 2020 scheduled for January 28-31, 2021. To learn more about the symposium, visit: https://ps2020.iaslc.org/.

The 2020 WCLC Virtual Presidential Symposium features:

First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743

Presenter: Professor Paul Baas, MD, The Netherlands Cancer Institute and The University of Leiden, Amsterdam.

ORIENT-11: sintilimab + pemetrexed + platinum as first-line therapy for locally advanced or metastatic non-squamous NSCLC

Presenter: Li Zhang, MD, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Gangzhou, China.

Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) positive NSCLC Patients: eXalt3

Presenter: Leora Horn, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, Tenn.

The Virtual Presidential Symposium also features presentations on the following:

Peri-Operative Adjuvant Immunotherapy for Resected Non-Small Cell Lung Cancer, presented by Dr. Matashiro Tsuboi, National Cancer Center Hospital East, Chiba, Japan

COVID-19 and Lung Cancer--an Update on TERAVOLT with Dr. Marina Garassino, Medical Oncology Division of the National Cancer Institute of Milan, Milan, Italy.

A Lung Cancer Patient's Manifesto for Modernizing Clinical Trials with Janet Freeman-Daily, lung cancer patient advocate and founder of #LCSM, Seattle.

Media Registration: For media guidelines and policies and to register for credentials, registration is now open at https://icsevents.eventsair.com/iaslc-virtual-ps/mediareg/Site/Register

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The all-virtual conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2020.iaslc.org.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.